Lipoxygenase, Angiogenicity, and Prostate Cancer Radioresistance
Abstract
Prostate cancer (PCa) is one of most common cancers affecting American men. Radiotherapy is a prevalent modality for the treatment of prostate tumor. Although radiation is capable of eradicating localized prostate tumors, nearly 30% of patients treated with potentially curative doses relapse at the sites of irradiation. Therefore, there is an imperative need to improve the success rate of radiotherapy for PCa. This proposal is focused on a role of 1 2-lipoxygenase (LOX) in modulating the radiation response of PCa cells. 12-LOX, the enzyme of interest, has already been identified as a promoter for PCa growth and progression. In our studies, 12-LOX was found to promote the resistance of PCa cells to radiotherapy. Inhibition of 12-LOX was found to sensitize PCa cells to radiotherapy and this sensitization maybe due to the activation of caspase-3, suggesting 12-LOX as a novel target for radiosensitization. Further studies will allow us to evaluate 12-LOX as a target to develop radiosensitizer for PCa radiotherapy. The knowledge gained from proposed study will have significant impact on future radiotherapy for PCa.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2005
- Accession Number
- ADA435094
Entities
People
- Dao-tai Nie
Organizations
- Wayne State University